Navigation Links
PharmaDirections is Co-inventor on Second Issued Formulation Patent Entitled “Layered Pharmaceutical Formulations”

Cary, NC (PRWEB) May 15, 2013

PharmaDirections has added another issued patent to their list of patents where they helped invent new technology for their clients. This one is United States Patent 8,318,788 which has been issued for “Layered Pharmaceutical Formulations”. This was a second patent that was a result of a collaborative formulation development effort between the scientists at Orexigen, PharmaDirections and their sub-contractors.

The technology is for multiple layered pharmaceutical formulations for drug products such as Contrave®, a treatment for obesity. The patent is assigned to Orexigen Therapeutics, Inc. who currently has an NDA for Contrave® under review at the FDA. In the example of an oral, controlled release dosage formulation, the middle layer is inert and dissolves in vivo to leave two separated drug containing layers intact until dissolution begins. This was done to separate potentially interacting layers from one another within the tablet and to allow each pharmaceutical layer to have its own controlled release dissolution profile. The pharmacokinetic modeling and formulation design was done at PharmaDirections.

"Our collaborative effort with Orexigen resulted in multiple accomplishments including this issued patent and the submission of 4 other patent submissions,” said Dr. Richard Soltero, President of PharmaDirections. “This brings us to 21 issued and issued patents for our clients where a PharmaDirections staff member was one of the inventors. We have helped a lot pharmaceutical companies find additional intellectual property by solving problems of bioavailability, stability or off-label competition.”

During the period from 2005 to 2008, PharmaDirections developed and manufactured several products for Orexigen including Contrave® and Empatic™. This relationship was published in Orexigen’s S-1statement issued in 2005 where it noted: “PharmaDirections is our primary drug development consultant and manages subcontractors on our behalf.”

About PharmaDirections:

PharmaDirections is a pharmaceutical project management and consulting group focused on CMC (Chemistry, Manufacturing and Controls), formulation development, preclinical and regulatory affairs. They utilize a mix of technical expertise, software and proprietary tools, such as GastroPlus™, when inventing new intellectual property for clients or developing formulations that solve difficult problems.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaDirections Celebrates 10 Years of Success for Their Virtual Biotech and Pharmaceutical Clients
2. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
3. PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
4. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
5. The Second Rarest Job in America: Atlanta Dentist Discusses New Bureau of Labor Statistics that Reveal Low Number of Prosthodontists
6. Dr. Ritchie Shoemaker Pleased to Announce Second Physician Achieves Shoemaker Protocol Certification for Treating Chronic Inflammatory Response Syndrome
7. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
8. Rust Remover That Clears Rust in Seconds Revealed by My Cleaning Products, Company Gives Out Samples of Product to Affirm Effectiveness
9. Genuine Bio Fuel Inc.’s Second Chance Program Proves to Be a Model for Successful Hiring in the Biodiesel Industry
10. Amgen Announces 2013 Second Quarter Dividend
11. Organic-Based Bed Bug Spray Kills Bed Bugs in Seconds, My Cleaning Products Releases Samples of the Product
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - ... ... ... With ...
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):